What Are The Chances Of Cardiff Oncology Inc (NASDAQ: CRDF) Becoming A Clear Buy?

After Hours

There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities. The stock was recently discussed on Yahoo Finance as it revealed that Cardiff Oncology Announces Upcoming Presentations at the AACR Annual Meeting 2024.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

Stocks Info

As a NASDAQ listed company, CRDF falls under the Healthcare sector while operating within the Biotechnology industry segment. The current market capitalization of Cardiff Oncology Inc is $238.59M. A total of 0.86 million shares were traded on the day, compared to an average of 1.63M shares.

In the most recent transaction, PACE GARY W bought 30,000 shares of CRDF for 1.37 per share on Dec 19 ’23. After the transaction, the Director now owns 697,761 company shares.

In spite of price targets being rarely accurate, it tends to exert some kind influence from time to time, and was often accepted by the market as having some value. In terms of 52-week highs and lows, CRDF has a high of $6.42 and a low of $0.94.

As of this writing, CRDF has an earnings estimate of -$0.25 per share for the current quarter. EPS was calculated based on a consensus of 4 estimates, with a high estimate of -$0.23 per share and a lower estimate of -$0.27. The company reported an EPS of -$0.22 in the last quarter, which was 21.40% higher than expectations of -$0.28.

Balance Sheet Annually/Quarterly

The balance sheet of a company shows what assets and liabilities a company has, as well as the amount, equity investors have invested. With the help of this information, a company’s financial ratios can be calculated to give investors an overview of the company’s prospects. CRDF’s latest balance sheet shows that the firm has $140.82M in Cash & Short Term Investments as of fiscal 2021. There were $3.12M in debt and $6.56M in liabilities at the time. Its Book Value Per Share was $1.56, while its Total Shareholder’s Equity was $140.42M.

Analysts Opinion

The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for CRDF is Buy with a score of 5.00.

Most Popular

Related Posts